Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma

Extravasation can present serious accidental complication of intravenous drug application. While monoclonal antibodies do not show the necrotic potential cytotoxic chemotherapy drugs, considerable inflammatory toxicity occur, necessitating standardized operating procedures for management their extravasation. Here, we report clinical course and dinutuximab beta extravasation in a 3-year-old child. Dinutuximab is chimeric antibody targeting GD2 disialoganglioside on surface neuroblastoma cells that has recent years gained significant importance treatment high-risk neuroblastoma, now contributing to both first- second-line therapy protocols. The reported here occurred when patient received cycle as continuous infusion over 10-day period after haploidentical stem cell transplantation relapsed neuroblastoma. extravasated caused local pain, swelling, hyperemia accompanied by fever an overall deterioration general condition. Laboratory diagnostics demonstrated increase C-reactive protein level total white blood count. Clinical consisted fluid therapy, dabbing with dimethyl sulfoxide (DMSO), analgesia dipyrone, well application antibiotics prevent bacterial superinfection severely immunocompromised host. considerably improved six days this regimen fully recovered day 20.